Introduction {#S1}
============

Essential tremor (ET) is a relatively common movement disorder associated with marked physical and psychosocial disabilities ([@B18]). Deep brain stimulation (DBS) has emerged as a safe and effective treatment for medically refractory ET ([@B1]). The ventral intermediate nucleus of the thalamus (VIM) has been mainly used as the target

1in DBS treatment for ET, and its stimulation is particularly effective in reducing hand tremor ([@B12]). However, the effects of DBS on midline symptoms, such as head tremor, have been inconsistent across studies and are less predictable. It has been reported that bilateral VIM-DBS reduces head tremor and that bilateral stimulation is more effective than unilateral DBS ([@B21]). However, bilateral VIM-DBS is associated with a higher risk of adverse side effects than unilateral VIM-DBS, including dysarthria, incoordination, and abnormal gait; DBS reprograming within the therapeutic window may not resolve these side effects ([@B19]). Moreover, 10--73% of patients who underwent VIM-DBS, particularly bilateral DBS, seems to develop observable tolerance and waning of benefits over the long-term treatment course ([@B5], [@B4]; [@B24]; [@B26]; [@B29]). Given these limitations, several DBS studies have explored the utility of targets other than the VIM in treating ET.

[@B17] reported a case of ET treated with unilateral DBS of a target positioned 3 mm below the VIM. After treatment, the patient's postural tremor was substantially improved. Another target of interest is the posterior subthalamic area (PSA), which includes the zona incerta and prelemniscal radiation. Emerging evidence from PSA-DBS studies ([@B16]; [@B25]; [@B8], [@B7]; [@B2], [@B3]; [@B14]; [@B30]) has indicated that stimulation of this target may be effective in reducing tremor, particularly when the tremor is difficult to control with VIM-DBS. Moreover, the adverse side effects of PSA-DBS seem to be mild and transient, without enduring side effects or stimulation tolerance ([@B23]; [@B13]). To date, however, only a few studies have been conducted to assess the safety and effectiveness of PSA-DBS for ET, and even fewer studies have explored the clinical effects of bilateral PSA stimulation ([@B32]; [@B15]). Therefore, we retrospectively assessed the clinical outcomes of a series of patients with medically refractory ET who underwent bilateral PSA-DBS. The study results should contribute to a better understanding of the clinical benefits and adverse-event profile of bilateral PSA-DBS in patients with refractory ET.

Materials and Methods {#S2}
=====================

In this retrospective case series, seven patients were identified from past medical records and followed up to the present. Each patient was clinically assessed and videotaped at regular intervals as part of standard care after they had received bilateral PSA-DBS surgery. Six patients were followed up for 12 months and one patient was followed up for 9 months. The average follow-up duration of the patient sample was 11.6 months. At the last follow-up, participating patients gave written informed consent for this study. The study was approved by the ethics committee of Ruijin Hospital School of Medicine, Shanghai Jiao Tong University, and was performed in accordance with the Declaration of Helsinki.

Surgical Procedure {#S2.SS1}
------------------

The surgical procedure included target localization and implantation of electrodes and pulse generators. Patients underwent 3.0-T magnetic resonance imaging (MRI) involving continuous scanning in the horizontal and coronal planes (slice thickness, 2 mm) and T2-weighted and post-gadolinium volumetric axial T1-weighted sequences. VIM targeting began with identifying the standard stereotactic coordinates relative to the posterior commissure (PC) on an anterior--posterior commissure (AC-PC)-aligned MRI; the position was 10.5--11.0 mm lateral to the wall of the third ventricle, 6.0--7.0 mm anterior, and 0 mm dorsal (Leksell Surgiplan, version 10.0, Elekta Instrument AB, Stockholm, Sweden). Subsequently, the PSA target was identified as being medial to the posterior tail of the subthalamic nucleus and lateral to the red nucleus on an AC-PC-aligned axial T2-weighted MRI at the level of the widest diameter of the red nucleus ([Figures 1](#F1){ref-type="fig"},[2](#F2){ref-type="fig"}).

![3 T magnetic resonance images. Target coordinates of the posterior subthalamic area (PSA) were 10 mm lateral, 7.7 mm anterior, and 3.4 mm superior. PSA (green) and ventral intermediate nucleus of the thalamus (red) contacts. **(A)** Coronal T2-weighted image. **(B)** Horizontal T1-weighted image. **(C)** Sagittal T1-weighted image.](fnhum-14-00016-g001){#F1}

![Positioning of the electrodes for posterior subthalamic area-deep brain stimulation. The colored areas represent different anatomical structures (blue, globus pallidus externus; green, globus pallidus internus; orange, subthalamic nucleus; red, red nucleus).](fnhum-14-00016-g002){#F2}

Our strategy was to target the VIM and PSA if both targets could be targeted. The trajectory was planned by using the PSA as the primary target. The coronal and sagittal angles were adjusted to attain a trajectory that traversed the VIM target. The planned trajectory was identified in coronal sections, beginning at the top of a gyrus and avoiding the ventricles, caudate nucleus, and blood vessels. The PSA was targeted in cases where the planned alignment was not achievable. In four patients, both the VIM and PSA were targeted. In the other three patients, both regions were not simultaneously targeted because we were unable to align them in one trajectory ([@B9]).

A stereotactic frame (Leksell) was installed under local anesthesia. The stereotactic pedestal was placed in parallel with the front and rear joint line (AC-PC). The head-computed tomography image was transmitted to the surgical planning system to determine the PSA target coordinates. Next, electrodes (3387, Medtronic or L102, PINS, Beijing Pins Medical Equipment Co., Ltd., Beijing, China) were implanted under general anesthesia. A pulse generator (37612 RC Medtronic or 102R PINS) was implanted under the clavicle. One week after DBS electrode implantation, the images of the patient's head and the preoperative MRI (using a Helix sequence) were merged to determine the position of the electrodes before programing. In this study, we focused on assessing the clinical effects of PSA stimulation; only the electrodes located in the PSA were activated.

Clinical Examination {#S2.SS2}
--------------------

In each patient, DBS was activated 1 week after surgery. We examined the clinical effects of stimulation after the location of each electrode was confirmed. Electrodes that displayed the best stimulation effect were selected for chronic stimulation. As outlined in the prior section, we focused on the electrodes located in the PSA.

A movement disorder specialist performed the clinical outcome assessments, using the Essential Tremor Rating Scale (ETRS) ([@B11]), before surgery and at 1-month, 6-month, and last (9- or 12-month) follow-up. Assessments focused on motor symptoms (items 1--9 of the ETRS), quality of life (items 15--21 of the ETRS), and complications, such as dysarthria, balance disorders, and hemiplegia. Additionally, the patients were videotaped with and without stimulation (stimulation was switched off during the preceding night) by another movement disorder specialist who was blinded to the patients' condition. This specialist also examined the videos.

Statistical Analysis {#S2.SS3}
--------------------

We performed a Kolmogorov--Smirnov test and the results indicated that nearly all variables were normally distributed and therefore suitable for parametric tests. However, it is difficult if not impossible to extrapolate data from a case series of seven patients to the overall population. Therefore, we utilized (non-parametric) Wilcoxon signed rank tests to make comparisons between the ETRS scores acquired under the different conditions. *P*-values less than 0.05 (two-sided) were considered statistically significant. The analysis was performed using SPSS 23 (IBM Corp, Armonk, NY, United States). Continuous variables are described as medians and interquartile ranges for parametric and non-parametric data distributions, respectively. The results are presented as the median ± interquartile range.

Results {#S3}
=======

Patients {#S3.SS1}
--------

The seven patients (six male, one female; mean age: 56.1 ± 14.3 years, [Table 1](#T1){ref-type="table"}) had undergone bilateral PSA-DBS at the Neurosurgical Center of Shanghai Ruijin Hospital between 2017 and 2018. At the time of surgery, all patients showed bilateral upper extremity postural tremor. Three out of the seven patients also displayed head tremor. Each patient was diagnosed with ET by using the diagnostic criteria of the Movement Disorder Society ([@B6]), including a history of therapeutic failure of at least one first-line medication. After clinical examination, the patients underwent bilateral PSA-DBS surgery by a medical team of movement disorder specialists and functional neurosurgeons.

###### 

Patient characteristics (*N* = 7)\*.

  ----------------------------- ------------------------
  Sex (men/women)               6/1
  **Age (years)**               
  Age of onset (years)          39.00 ± 9.00 (19--46)
  Age of surgery (years)        59.00 ± 21.00 (29--69)
  Duration (years)              20.00 ± 11.00 (7--30)
  Previous VIM-DBS surgery      1 (bilateral)
  Follow-up duration (months)   9 (1/7) or 12 (6/7)
  ----------------------------- ------------------------

VIM-DBS, ventral intermediate nucleus-deep brain stimulation. \*Data values represent median ± interquartile range (min--max) unless indicated otherwise.

ETRS Data {#S3.SS2}
---------

The patients' ETRS scores before and after bilateral PSA-DBS surgery are presented in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. At 1-month follow-up, the patients' motor symptoms were improved, on average, by 84.2%, head tremor by 100.0%, upper limb tremor by 76.0%, and quality of life by 81.25%. These clinical benefits were significant and maintained at 6-month and last (9- or 12-month) follow-up ([Table 2](#T2){ref-type="table"}). No significant differences existed between the mean ETRS scores obtained at 6-month and last follow-up.

###### 

Essential tremor rating scale scores before and after bilateral PSA-DBS (*N* = 7)\*.

  **Item**                         **Top score**   **Baseline**    **One month**   **Improvement**   ***p*-Value**   **Six months**   **Improvement**   ***p*- Value**   **Last follow-up^\#^**   **Improvement**   ***p*-Value**                             
  -------------------------------- --------------- --------------- --------------- ----------------- --------------- ---------------- ----------------- ---------------- ------------------------ ----------------- --------------- --------------- --------- -------
  Tremor rate (items 1--9)         80              19.00 ± 10.00   3.00 ± 4.00     14.50 ± 13.00     84.21%          0.018            2.00 ± 3.00       14.50 ± 14.50    89.47%                   0.018             2.00 ± 2.00     14.50 ± 14.50   89.47%    0.018
  Head tremor (item 4)             4               1.00 ± 2.25     0.00.±0.00      1.00 ± 2.00       100.00%         0.048            0.00 ± 0.00       1.00 ± 2.00      100.00%                  0.048             0.00 ± 0.00     1.00 ± 2.00     100.00%   0.048
  Upper tremor (items 5, 6)        24              12.50 ± 3.00    3.00 ± 2.00     11.00 ± 3.50      76.00%          0.018            2.00 ± 2.00       11.00 ± 3.50     84.00%                   0.018             1.00 ± 1.50     11.00 ± 4.50    92.00%    0.018
  Rest                             8               4.50 ± 5.00     0.00 ± 0.00     3.50 ± 4.50       100.00%         0.031            0.00 ± 0.00       3.50 ± 4.50      100.00%                  0.031             0.00 ± 0.00     3.50 ± 4.50     100.00%   0.031
  Posture                          8               5.00 ± 1.50     1.00 ± 1.50     5.00 ± 1.50       80.00%          0.017            1.00 ± 1.50       4.50 ± 1.50      80.00%                   0.018             0.00 ± 1.50     4.50 ± 1.50     100.00%   0.017
  Action                           8               5.50 ± 1.50     1.00 ± 2.50     4.50 ± 1.50       81.82%          0.018            1.00 ± 2.00       4.50 ± 1.50      81.82%                   0.018             1.00 ± 2.00     4.50 ± 1.50     81.82%    0.018
  Quality of life (items 15--21)   28              16.00 ± 9.00    3.00 ± 5.00     15.00 ± 9.00      81.25%          0.017            3.00 ± 4.00       14.00 ± 8.00     81.25%                   0.017             2.00 ± 4.00     14.00 ± 9.00    87.50%    0.017
  Speech (item 15)                 4               0.00 ± 1.00.    0.00 ± 1.00     0.00 ± 1.00       --              0.317            0.00 ± 0.00       1.00 ± 1.00      --                       0.083             0.00 ± 0.00     1.00 ± 1.00     --        0.083

DBS, deep brain stimulation. Improvement refer to symptom change from baseline to follow-up with stimulation on. \* Data values represent median ± interquartile range unless indicated otherwise.

\#

Six patients were followed up to 12 months; 1 patient was followed up to 9 months.

###### 

Essential tremor rating scale raw scores of each patient (DBS ON).

  **Patient**   **Head tremor (item 4)**   **Upper tremor (items 5, 6)**                            
  ------------- -------------------------- ------------------------------- --- --- ------ ----- --- ---
  1             2                          0                               0   0   14.5   1     1   0
  2             0                          0                               0   0   15     3     3   2
  3             2                          0                               0   0   11     5     3   3
  4             0                          0                               0   0   12     5.5   4   4
  5             0                          0                               0   0   12     3     3   3
  6             3                          0                               0   0   18.5   0     1   0
  7             2                          0                               0   0   12.5   1     1   1

Electrode Position and Parameters {#S3.SS3}
---------------------------------

One week after surgery, the DBS parameters were set to the following values: pulse voltage = 1.5--2 V, frequency = 145 Hz, and duration = 60 μs, using monopolar stimulation. Subsequently, the stimulation parameters were adjusted according to the patients' symptoms and extent of adverse side effects in an effort to achieve the clinically best outcomes ([Table 4](#T4){ref-type="table"}). Ultimately, the stimulation parameters were set to 1.75--3.35 V, 115--160 Hz, and 50--80 μs (the Pins device pulse began at 30 μs).

###### 

Electrode position and final stimulation parameters.

  **Patient**   **Contact**   **Target**   **Voltage (V)**   **Frequency (Hz)**   **Pulse (μs)**
  ------------- ------------- ------------ ----------------- -------------------- ----------------
  1             C + 4−        L-PSA        1.75              125                  60
                C + 0−        R-PSA        2.45              115                  60
  2             C + 8−9−      L-PSA        2.5               160                  60
                C + 0−1−      R-PSA        2.5               160                  60
  3             C + 8−9−      L-PSA        3.0               145                  60
                C + 1−        R-PSA        2.35              145                  60
  4             C + 6−        L-PSA        2.15              135                  50
                C + 2−        R-PSA        2.0               135                  50
  5             C + 6−5−      L-PSA        3.35              135                  60
                C + 1−0−      R-PSA        2.15              135                  60
  6             C + 6−5−      L-PSA        2.65              145                  80
                C + 1−        R-PSA        2.35              145                  60
  7             C + 5−6−      L-PSA        2.35              145                  60
                C + 1−2−      R-PSA        2.65              145                  80

PSA, posterior subthalamic area; R, right; L, left.

Adverse Side Effects {#S3.SS4}
--------------------

Four out of the seven patients displayed mild dysarthria associated with the stimulation. Two patients in the sample developed a mild balance disorder. Both adverse side effects were resolved during the off-state condition at 6-month follow-up and did not reappear thereafter. One patient in the sample developed postoperative paralysis in the right arm due to edema in the trajectory of the left lead; this adverse event was similarly resolved at 6-month follow-up ([Figure 3](#F3){ref-type="fig"}).

![Postoperative brain magnetic resonance (MR) images in a patient who developed right paralysis due to encephaledema. **(A)** Position of electrodes. **(B)** MR image taken 1 week postoperatively. **(C)** MR image taken 8 weeks postoperatively.](fnhum-14-00016-g003){#F3}

Discussion {#S4}
==========

In this study, we explored the clinical benefits and adverse event-profile of bilateral PSA-DBS in several patients with medication-refractory ET. The results showed that bilateral PSA-DBS was associated with a significant improvement in patients' motor symptoms, particularly upper limb tremor and quality of life. These clinical benefits were evident at 1-month follow-up and maintained at 6-month and final (9- or 12-month) follow-up. At final follow-up, patients' motor symptoms were reduced by almost 90% compared with the severity of their symptoms before DBS treatment. Interestingly, bilateral PSA-DBS was also associated with a marked improvement in head tremor. The latter finding compares favorably with the 30--57% improvement in head tremor seen after unilateral VIM-DBS and with the 51--86% improvement observed following bilateral VIM-DBS ([@B21]; [@B22]; [@B27]; [@B31]). The present results indicate that bilateral PSA-DBS could provide a valuable alternative treatment for medically intractable ET, warranting further research into its clinical utility and comparative effectiveness.

Moreover, bilateral PSA-DBS was associated with mild and tolerable side effects in this study. Although dysarthria (*n* = 4) and balance disorder (*n* = 2) emerged in the initial stages of treatment, all adverse side effects were transient and subsequently resolved or reduced by DBS reprograming without affecting the therapeutic effects ([Table 5](#T5){ref-type="table"}). Indeed, previous studies have similarly shown that decreasing the pulse width or frequency or other parameter adjustments offer a powerful means to eliminate or reduce adverse side effects while maintaining the clinical benefits of DBS treatment to patients ([@B28]; [@B10]; [@B20]). Thus, bilateral PSA-DBS could provide not only an effective but also a relatively safe treatment for refractory ET.

###### 

Stimulation parameters at 6-month and last follow-up^\#^.

  **Patient**              **Six months**         **Last follow-up**                           
  ------------- ---------- ---------------- ----- -------------------- ---------- ------ ----- ----
  Patient 1     C + 4−5−   2.25             125   60                   C + 4−     1.75   125   60
                C + 0−1−   2.25             115   60                   C + 0−     2.45   115   60
  Patient 2     C + 8−9−   2.5              160   60                   C + 8−9−   2.5    160   60
                C + 0−1−   2.5              160   60                   C + 0−1−   2.5    160   60
  Patient 3     C + 8−     2.9              160   70                   C + 8−9−   3.0    135   60
                C + 1−     2.3              160   60                   C + 1−     2.35   135   60
  Patient 4     C + 6−     2.15             135   50                   C + 6−     2.15   135   50
                C + 2−     2.1              135   50                   C + 2−     2.0    135   50
  Patient 5     C + 6−5−   3.35             135   60                   C + 6−5−   3.35   135   60
                C + 1−0−   2.15             135   60                   C + 1−0−   2.15   135   60
  Patient 6     C + 6−5−   2.25             145   80                   C + 6−5−   2.65   145   80
                C + 1−     1.75             145   60                   C + 1−     2.35   145   60
  Patient 7     C + 5−6−   2.15             145   60                   C + 5−6−   2.35   145   60
                1−2 +      2.65             145   80                   1−2 +      2.65   145   80

\#

Six patients were followed up to 12 months; 1 patient was followed up to 9 months.

It was concerning, however, that one of the patients developed paralysis in the right arm due to edema in the trajectory of the left DBS lead. This adverse event was linked to the close proximity between the electrode trajectory and motor cortex. To adjust this, we used a large coronal and sagittal angle so that the electrodes crossed posterior to the central gyrus and encompassed both the PSA and VIM in one trajectory. Subsequently, the patient's paralysis was resolved at 6-month follow-up.

The results of this case series are promising but should be considered as tentative and preliminary given the study limitations. The study included only a small patient sample, did not include a comparison group, and had significant potential for bias and confounding. Accordingly, the results may be categorized as class IV evidence. In addition, the patient sample was clinically heterogenous and the DBS device used was not identical in all patients. Thus, additional research is required to support or refute the present findings before any firm conclusions can be drawn.

Conclusion {#S5}
==========

This study indicated that bilateral PSA-DBS could offer an effective and safe alternative treatment for at least some cases of medically intractable ET. The results seem to us sufficiently promising to warrant the initiation of larger and well-controlled studies to assess its clinical utility, adverse-event profile, and comparative effectiveness.
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